The presence of cytogenetic aberrations on mesenchymal stem cells (MSC) from myelodysplastic syndrome (MDS) patients is controversial. The aim of the study is to characterize bone marrow (BM) derived MSC from patients with MDS using: kinetic studies, immunophenotyping, fluorescent in situ hybridization (FISH) and genetic changes by array-based comparative genomic hybridization (array-CGH). In all 36 cases of untreated MDS were studied. MDS-MSC achieved confluence at a significantly slower rate than donor-MSC, and the antigenic expression of CD105 and CD104 was lower. Array-CGH studies showed DNA genomic changes that were proved not to be somatic. These results were confirmed by FISH. To confirm that genomic changes were also present in freshly obtained MSCs they were enriched by sorting BM cells with the following phenotype:
Introduction
Myelodysplastic syndrome (MDS) are a group of clonal disorders of pluripotent hematopoietic stem cells, characterized by ineffective hematopoiesis and a heightened potential to evolve into acute myelocytic leukemia. 1 MDS is the result of a multi-step sequence of genomic injures to Bone Marrow (BM) stem cell. Although clonal chromosomal abnormalities are detected in 40-70% of de novo MDS, and in 95% of therapy-related MDS, there is no cytogenetic abnormality specific for MDS. 2 In the pathophysiology of MDS not only cytogenetic and molecular abnormalities are implicated but also some other factors such as DNA hypermethylation, immune dysregulation and an increased frequency of apoptosis in the BM cells. 3 The hematopoietic microenvironment plays a role in the physiology of hematopoiesis, controlling the formation of blood cells through the production and secretion of cytokines and extracellular matrix molecules. Mesenchymal stem cells (MSC) are key components of the hematopoietic microenvironment and the research on their implication in several diseases is expanding. Microenvironment is involved in the pathophysiology of MDS, 4 and the abnormal production of certain cytokines by BM-derived fibroblasts of MDS is nowadays accepted. 5, 6 Nevertheless, the question of whether MSC from MDS patients are abnormal is not clear. Although some groups have reported that MSC display both a normal growth pattern and a normal surface antigen expression as compared with MSC from healthy individuals, [7] [8] [9] other authors have shown discrepant results. 4, 8, 10 Even more confusion exists regarding whether or not MSC from MDS display cytogenetic abnormalities. The studies in this field are scanty and again they show discrepant results from absence of chromosomal markers, 7, 11 to the presence of karyotypic aberrations such as hypodiploid cells. 4, 8, 10 This study aimed to analyze the characteristics of MSC from MDS patients including the growth pattern, the immunophenotype and their cytogenetic characterization by array-based comparative genomic hybridization (array-CGH).
Materials and methods

Patient characteristics
36 BM cells from 'de novo' MDS, corresponding to 33 patients, were included in the study. Male/female ratio was 17/16 and median age was 70 years (range, 34-89 years). MDS diagnosis was established by peripheral blood counts and morphology, BM morphology and cytogenetic analyses and classified according to the WHO proposals. 12 Patients' characteristics are summarized in Table 1 . Three cases not previously treated were also analyzed at progression (cases 16, 18 and 20) . None of them had received treatment during this period of time, other than supportive therapy. Normal BM samples were obtained from 15 healthy donors, eight men and seven women, with a median age of 57 years (range, 37-88 years). Written informed consent was obtained from all patients and donors according to the ethical guidelines of our institution.
Isolation and expansion of MSC
Mononuclear cells from BM were isolated by centrifugation (1200 r.p.m. for 30 min) using Ficoll-Paque Plus (Amersham Biosciences AB, Uppsala, Sweden) density gradient. 13 Mononuclear cells were plated at a concentration of 1 Â 10 6 cells/cm 2 and cultured in Dulbecco's modified Eagle's medium (Gibco, BRL, Invitrogen Corporation, Paisley, UK) supplemented with 10% fetal bovine serum (FBS; BioWhittaker, Lonza, Veviers, Belgium) and 1% antibiotics (PenicillinStreptomycin, Gibco, Invitrogen Corporation). Every 5 days non-adherent cells were removed and the medium was changed. When the cultures reached 80% confluence, they were trypsinized (0.05% Trypsin-EDTA; Gibco, Invitrogen Corporation), 14 and further expanded. Cultures were incubated at 37 1C in an atmosphere of 5% CO 2 air.
Morphological analysis and cell surface antigen analysis
The morphology of the cells was examined every 5 days under a phase-contrast microscope.
MSC were characterized according to the International Society of Cell Therapy consensus antibody panel. 15 The monoclonal antibodies used were: anti-CD34-APC, -CD19-APC, -CD45-PerCPCy5.5, -HLA-DR-PerCPCyC5.5, -CD14-FITC, -CD56-PE, -CD62L-PE, -CD49A-PE, -CD117-PE (Becton Dickinson Biosciences, San José, CA, USA), anti-CD90-FITC, -CD73-PE, -CD166-PE, -CD106-PE, -CD104-PE, -CD49B-FITC (BD Biosciences Pharmingen, San José, CA, USA), anti-CD54- 16 To compare the expression level of each antigen the mean channel fluorescence intensity was related with the isotopic control before comparing with the rest of the cells.
Differentiation assays
To fulfil the International Society for Cellular Therapy requirements for MSC definition, adipogenic, osteogenic and chondrogenic differentiation was performed.
To induce osteoblastic and adipocytic differentiation, MSC from cases number 8, 10, 14, 16 and 31 were harvested and platted at 4th passage on a chamber slide system (SlideFlask, Nunc, Roskilde, Denmark). When the cells had reached a confluence of above 80%, the medium was changed to the specific differentiation medium that was changed every 3-4 days during the 14 days. The osteoblastic differentiation medium was composed of DMEM, 10% FBS, 1% antibiotics and 10 mM of b-glycerophosphate (Sigma-Aldrich Inc., Milwaukee, WI, USA). The adipocytic medium was composed of Iscove's modified Dulbecco's Medium (Gibco, Paisley, UK), 10% FBS, 1% antibiotics, 10% horse serum and 5 Â 10 À7 hydrocortisone (Sigma-Aldrich Co). To evaluate the osteoblastic differentiation, the cells were stained with alkaline phosphatase using a commercial kit (Super-Sensitive/HC Detection Systems, BioGenex, Duiven, The Netherlands). The staining with Oil-red-O (Merck KGaA, Darmstadt, Germany) was used in the adipocitic differentiation. 14 For chondrocytic differentiation, MSC from case numbers 8, 10 and 14 were harvested at 3rd passage, and 1 Â 10 6 cells were centrifuged for 10 min at 1200 r.p.m., in a 15 ml conical polypropylene tube. The pellet was cultured with 0.5 ml of the commercial differentiation medium (ChondroDiff, Mitenyi Biotec, Bergisch Gladbach, Germany). The medium was changed every 4 days until day 21. This pelleted micromass 
DNA analysis
To analyze the percentage of MSC that were at different stages of cell cycle a DNA analysis was performed. MSC from cases 8, 9, 10, 13 and 14 were harvested at 3rd passage, and the pellet was washed with PBS. Cells were incubated at room temperature with ribonuclease (40 U/ml) (Sigma Diagnostics Inc.) for 10 min, and later with 1 mg/ml propidium iodide (Sigma Diagnostics) for 15 min also at room temperature. The PI fluorescence was measured using the FACSCalibur flow cytometer, and the analysis was performed with the Paint-A-Gate software. 18 
Apoptosis assays
MSC from MDS, case numbers 8, 9, 10, 13 and 14, were analyzed on 3rd passage performing an apoptosis assay, using the Annexin V-PE and 7-ActinomicinD-PerCPCyC5.5, kit (BD Pharmingen, BD Biosciences Pharmingen, San Diego, CA, USA), following manufacturer's instructions. 19 
Isolation of MSCs
Isolation of MSCs directly from BM was performed, in cases 33, 34, 35 and 36, using a FACSAria flow cytometer (Becton Dickinson Biosciences-BDB-, San Jose, CA, USA), equipped with the FACSDiva software (BDB). Prior to sorting, cells were stained with a single four-color combination of monoclonal antibodies (MAb): anti-CD45-FITC (Miltenyi Biotec)/anti-CD73-PE (BD Biosciences Pharmingen, San José, CA, USA)/ anti-CD34-PeCy5 (Immunotech Coulter Company, Marseille, France)/anti-CD271-APC (Miltenyi Biotec), according to wellestablished stain-and-then-lyse-and-wash procedures which have been described earlier. 20 The strategy used for the identification of MSC (CD45
is illustrated in Figure 1a . Owing to the low proportion of MSC in the sample, acquisition was performed in two consecutive steps to increase the sensitivity of the analysis. First, a total of 50 000 events corresponding to the total nucleated cells present in the sample were acquired. In a second step, acquisition through a 'live gate' drawn on the CD73 þ /CD271 þ region in which MSCs are located was performed ( Figure 1b ). The purity of the isolated cell populations was evaluated after acquiring 3 Â 10 3 cells corresponding to the FACS-sorted cell fraction (FACSAria flow cytometer) and it was 499% (Figure 1c) . 20 Array-CGH and FISH analysis of MSC Array-CGH analysis of cultured MSC. Genome-wide analysis of DNA copy number changes of MSC from 13 cases was performed using array-CGH. Slides containing 3032 bacterial artificial chromosomes (BACs) were produced in 'Centro de Investigació n del Cáncer' (Salamanca, Spain). The particular BAC and P-1-derived artificial chromosome set used to produce this array is distributed to academic institutions by the Welcome Trust Sanger Institute (Cambridge, UK) and contains targets spaced at E1 Mb density over full genome, a set of subtelomeric sequences for each chromosome arm and a few hundred probes selected for their involvement in oncogenesis. The clone content is available in the 'Cytoview' windows of the Sanger Institute mapping database site, Ensembl (http:// www.ensembl.org/). According to this database, clones were ordered along the chromosomes. These clones were isolated from their bacterial cultures with the relevant antibiotics and the DNA was extracted with the standard protocol of Welcome Trust Sanger Institute. Here, 10 ng of DNA (BAC/PAC) was used as a template for three DOP-PC. 22, 23 These products were ethanol precipitated and dissolved in distilled water. A minimum of three replicates per clone were printed by Microgrid II (Biorobotics, Ann Harbor, MI, USA) on each slide (Ultragaps Coated Slides, Corning, NY, USA) using the aqueous dimethylsulfoxide buffer as spotting solution. Briefly, for labelling reactions, 1 mg of nonamplified genomic DNA, test and reference were digested separately with DpnII restriction enzyme (New England Biolabs, Beverly, MA, USA). For microarray hybridization, the digested DNAs were separately labelled using random primers (Bioprimer labelling kit, Invitrogen, Paisley, UK) and cyanine dye-3-dCTP and cyanine dye-5-dCTP fluorescent dye to paired hybridization samples (Amersham Biosciences, Uppsala, Sweden). The incorporation of the label nucleotide was quantified using the Nanodrop spectrophotometer. Labelled test and reference DNAs were mixed equitably, co-precipitated in the presence of Cot-1 human DNA (Roche, Indianapolis, IN, USA) with ethanol, washed and resuspended in hybridization solution (50% Formamide, 10% Dextran sulfate, 2 Â standard saline citrate, 10 mM Tris pH 7.6, 2.7% sodium dodecyl sulfate and 10 mg/ml of yeast tRNA). DNA mixtures were hybridized to the arrays in the TECAN HS4800 Pro according to the manufacturer's recommended protocol. Images and signal intensities were acquired using GenePix4000B (Axon Instruments, Burlingame, CA, USA) dual laser scanner in combination with GenePixPro4.0 (Axon Instruments) imaging software.
Image and data analysis. Spot intensities measured by the GenePix Pro 4.1 software (Axon Instruments, Wetsbur BV, Leuden, The Netherland). Pixel intensities for each feature were integrated and median values were determined, and the local background was calculated. For each spot the intensities were corrected by subtracting the local background for both wavelengths, and only spots with signal intensities al least threefold above background signal intensities were included in the analysis. The median of the ratios of all spots was calculated and used to normalize all data points. From each feature, the log 2 value of the average of the normalization ratios of the spots was calculated and used to display the data. In addition, fluorescence ratios were normalized for each microarray using the print-tip loess method and the background subtraction with the Diagnosis and Normalization Arrays Data tool. 24 The cutoff level was determined for each individual experiment after avering the ratios from the two color-switch hybridizations and subsequent for normalization, and calculate the mean and s.d. to define the cutoff level as means plus/minus two times the s.d. The clones that showed possible changes were submitted to the database of genomics variants (http://projects.tcag.ca/variation/) and chromosomal imbalances and phenotype in humans using Ensembl Resources (DECIPCHER: http://www.sanger.ac.uk/ PostGenomics/decipher/.
Clustering
Unsupervised clustering. We converted the relative ratio value for each BAC clones in each sample to score of 1 (gain/amplified), 0 (no change), or À1 (loss) based on the 2 s.d. standards described above and analyzed with Cluster and TreeView) 25 (Cluster and TreeView software) based on the average linkage method with the centered correlation metric was used (or Pearson Uncentered).
Supervised. Sam analysis was used (http://www-stat.stanford. edu/~tibs/SAM) 26 to identify BACs that segregate subgroups on MSC. BACs with an s.d. of zero across the data set before analysis were removed.
The array data has been deposited in the gene expression omnibus database, the accession number is GSE10822.
Array-CGH on sorted-uncultured MSC. After the sorting, Genomic DNA was extracted using a standard proteinase K digestion followed by phenol/chloroform extraction and resuspended in TE buffer pH 7.5. The concentration of the samples was measured by spectrophotometer (Nanodrop ND-100 spectrophotometer; Nanodrop Technologies, Rocland, DE, USA).
GenomiPhi DNA amplification kit was used following the manufacturer's instructions. Briefly, 1 ml of template was mixed with 9 ml of sample buffer. The mixture was denatured at 95 1C for 3 min and immediately cooled at 4 1C for a minimum of 10 min a combinational of 9 ml of reaction buffer with 1 ml of the enzyme was added to the cooled sample and then incubated at 30 1C for 16 h overnight. Inactivation of the enzyme was performed by heating the sample for 10 min at 651C, which was the cooled to 4 1C. The postamplification cleanup was achieved by ethanol precipitation using the sodiumacetate/ EDTA. Given that negative controls pf Phi29 amplified reactions 
a gate is performed in the CD73
þ /CD271 þ region in which MSCs are located (b). Finally the purity of the population is analyzed (c) being 499%. The MSC population is indicated in black, the contaminating cells in gray.
Mesenchymal stem cells of 5qÀ syndrome O Lopez-Villar et al also show a smear in agarose gel, we determined whether the amplified products contained actual genomics by performing a PCR, using specific primers.
Array-CGH was carried out as described in the previous paragraphs with minor modifications. For obtaining optimal results in experiments, both test and reference DNA were amplified using the same amount of starting DNA.
FISH analysis of MSC. To confirm array-CGH results
fluorescent in situ hybridization (FISH) analysis were performed with the probe obtained from the BAC RPCI11-440G22 (1q31.12), and BAC RP11-132L11 (7p13). DNA probes were labeled either with biotin-11-dUTP or with digoxigenin-11-d-UTP by a standard nick translation reaction. The hybridization was performed according to previously reported procedures. 27 Briefly, probes were denatured and preannealed with Cot-1 DNA and hybridized overnight on pretreated denatured chromosome spreads. After washing, the biotin-labeled probes were detected with two layers of avidin-FITC.
Array-CGH of hematopoietic cells
Mononuclear cells from peripheral blood of three cases, numbers 21, 22 and 24, were isolated at diagnosis and used as controls to be sure that changes were not somatic changes. DNA from these cells was isolated and the array performed as described for MSC.
Array-CGH of T lymphocytes from peripheral blood
T lymphocytes of case numbers 33, 34, 35 and 36 were obtained from peripheral blood; after separating mononuclear cells by density gradient, the T lymphocyte population was selected by CD3 using the immunomagnetic protocol for AutoMACS (CD3 microbeads human, MACS Miltenyi Biotec). DNA from these cells was isolated and the array was performed as described for MSC.
14,28
Statistics
The SPSS version 15.0 software (Chicago, IL, USA) was used for statistical analysis.
The central tendency of data was measured by the median and the dispersion of values around the median was expressed as the range. Statistical analysis was performed by using the Student's t-test. Values of Po0.05 were considered significant.
Results
MSC cultures
MSC confluent layers were obtained in all healthy donors, with a median number of five passages (range, 2-7), and time to reach confluence of 15.5 days (11.6-30). However, when expansion of MSC from MDS patients was assessed, more time (Po0,05) was needed until confluence was achieved, 23.5 days (12-90) (Supplementary Figure 1) and only able to survive the third passage (range, 0-5). Moreover in six MDS cases, cells did not reach confluence and they could not be expanded (Cases 11, 20, 26, 27, 29 and 30) . Also MSC layers morphology was different in donors and patients. Cells from donors showed the characteristic fibroblastlike aspect, but MSC from MDS seemed to be more 'thick and granular' (Figure 2 ).
Phenotypic analysis of MSC
It should be pointed out that the purity of MSC was above 98% in all cases (Supplementary Figure 2) . Cells from cultures were consistently devoid of hematopoietic cells (HC) being negative for hematopoietic antigens CD45, CD34, CD14, CD19 and HLA-DR and were positive for the following antigens CD73, CD90, CD166, CD105, CD104, CD106. When the fluorescence intensity of surface antigens of MSC of MDS was compared with those of MSC from 15 healthy donors, a lower expression of CD105 and CD104 was observed (Supplementary Figure 3 Po0.05). All other antigens analyzed showed a similar expression pattern.
Differentiation assays
To further characterize MSC from MDS, differentiation assays recommended by The International Society for Cellular Therapy were performed. 15 Adipocytic and osteoblastic differentiation assays were performed in five cases, (8, 10, 14, 16 and 31) . Chondrocytic differentiation was performed in three cases (8, 10 and 14) .
Osteoblastic and Adypocitic differentiation was achieved with a similar efficiency than those of normal MSC. However, when chondrocytic differentiation was analyzed we could observe an impaired capacity of cells from MDS to differentiate to chondrocyte lineage as the disposition of collagen II-positive cells in MDS cases is different from those observed in healthy donors (Supplementary Figure 4) .
DNA analysis and apoptosis studies
To know why cell expansion was impaired in MSC from MDS patients, cell cycle analysis was performed in five cases (8, 9, 
Array-CGH analysis of MSC
Array-CGH arrays were performed in 17 cases.
13 MDS cases were analyzed by array-CGH after MSCs expansion : (Cases 1, 8, 10 In other four cases (33, 34, 35 and 36) array-CGH were performed in parallel, after MSCs sorting and in after 2nd passage expanded MSCs.
All the cases included in the array-CGH analysis showed some alterations, with gains more frequent than losses. None of the clones showing modifications have been described to be associated with polymorphic variations except RP11-153P4 located on 9q34.2. Even more, in the three cases in whom array-CGH were performed in HC from peripheral blood and in expanded MSC, the abnormalities found in MSC were not present in HC. Furthermore, array-CGH were performed in T lymphocytes from four patients and those cells did not have the cytogenetic abnormalities found neither on the expanded MSC nor on sorted MSC.
The most frequent minimal regions with gains (with more than one consecutive clone gain) are shown in Table 2 , and they are localized in 19p13.3, 11q13.1 and 20q13.33. Supplementary Table 1 of supplemental data shows the gains and losses in the different chromosomal regions.
When unsupervized hierarchical cluster analysis of the array-CGH was performed, two major genetic subgroups emerged. Seven samples were grouped in Cluster I, and six samples in Cluster II (Figure 3) .
Interestingly, five out of the six cases included in cluster II corresponded to 5qÀ syndrome patients (cases 21, 22, 24, 26 and 27). The other patient had been diagnosed as refractory anemia (RA) but when the diagnosis was revised FISH analysis revealed 4% of 5qÀ cells (case 1), and by morphology hypoplastic erythropoiesis and 8% of mononucleated megakaryocytes were observed.
By contrast, cluster I grouped cases other than 5qÀ syndromes except for one patient diagnosed as a refractory anemia with excess of blasts type 1 (RAEB-1) but with 5q deletion (case 12).
Significance analysis of microarrays indicated that the differences between these two clusters occurred just in 26 bacterial artificial chromosome (BAC). When looking at these clones and taking into account only regions with at least two consecutive clones affected, chromosomal regions 11q13, 17q25, 19q13, 20q13 and 22q13.2 were gained in 100 or 80% of the cases in cluster II; by contrast a normal copy or deletion status was observed in cluster I (Supplementary Table 2 ).
To confirm the gains of these regions a FISH analysis was performed using the DNA probes from 1q31.12 (RPCI11-440G22). As it can be observed in Figure 3 , the gains in chromosome 1q31 in MSC were confirmed.
It should be pointed out that the concomitant analysis of array-CGH on HC from three cases and T lymphocytes from other four cases allowed us to show that the alterations of MSC were not present either on HC or on T cells and also showing that these alterations are not constitutional. Supplementary Figure 5 shows an example.
When sorted MSCs were analyzed also some genomic changes could be observed, the following regions being the most frequent gains observed among the cases: 1q31, 10q26 and 20q13. It is mandatory to point out that the purity of the sorted MSC was above 99% (Figure 1 ). To confirm these genomic gains a FISH analysis was performed using the DNA probe from the 7p13 BAC that showed a very high genomic gain at this level in case number 34. The expanded MSCs from the same patient were analyzed. As shown in Supplementary Figure  6 several signals can be observed confirming the genomic gain.
Discussion
The interactions between the malignant clone and the BM microenvironment have recently emerged as an important Table 2 Commonly gained regions of copy number changes identified in MSC of patients with MDS assessed by array-CGH player in cancer development. 29 However, little is known about the characteristics of the BM stroma cells from cancer patients.
In this study we have observed that in MDS patients, the MSC, Fthe progenitors of BM stromal cellsFdisplay an abnormal phenotype, function and genetic features.
The development of MDS is a complex process and a multistep model has been proposed. 1, 3, 30, 31 In this model an abnormal hematopoietic clone would interact with an altered BM microenvironment. Newer knowledge is appearing showing new molecular alterations involved in MDS development, recently it has been shown that ribosomal proteins could participate in some MDSs development such as 5qÀ syndrome. 32 Although there is intensive research on the role of stromal cells in the pathophysiology of inefficient hematopoiesis, 6, 8, 33 ,34 a consensus has not been reached. As the stroma is a network of different cell types and molecules we decided to focus on MSC to have a homogeneous cell population devoid of HC. With our selection method the purity of MSC was above 98% in all cases.
The growth kinetics of MSC from MDS patients has been controversial with some authors showing an impaired expansion potential 4, 8 and others obtaining a growth pattern similar to those of normal BM. 7 Our results support the former data with a lower expansion capacity of MSC from MDS patients. The differences with other reports may be because of the great variability observed among MSC growth in MDS or because cases with absence of growth were not included in the analysis.
Regarding MSC immunophenotype, the expression of CD90 has been previously reported to be lower in MSC from MDS. 8, 10 In our series this feature was also observed but differences did not reach statistical significance. By contrast MDS-derived MSC showed a significant lower expression of two adhesion molecules (CD 104 and CD 105); this lower expression could be involved in the altered relationship between BM stroma and HC. The intensity of CD 105 is not always analyzed and it has just been found to be lower in one study 10 and CD 104 has not been previously analyzed.
To gain insight on the mechanisms involved in the lower expansion capacity, cell cycle and apoptosis analysis were performed. No differences between MDS and controls, in the cell cycle distribution were observed and although apoptosis was slightly higher in MDS patients the small differences do not justify the cell growth impairment present in this disorder. Accordingly further studies are needed to explain the low expansion capacity of MDS.
Regarding cytogenetic abnormalities, Soenen-Cornu et al. 7 have shown that MSC from MDS patients do not harbor the same cytogenetic abnormalities present on their HC counterpart. Nevertheless, other groups have reported the existence of chromosomal aberrations in MSC from MDS. 8, 9 To gain more insight in this field we have conducted array-CGH studies, which allow to study a greater number of genes than conventional cytogenetic or FISH, and in all cases some abnormalities were observed but when control's MSCs were analyzed they did not display similar changes. In addition the chromosomal imbalances present in the MSC were different than the ones observed in the HC. To confirm that these genomic changes were present in MSCs, a FISH analysis using the same probes than those used in array-CGH were done and the genomic gains were confirmed (Figure 4) .
It should be stressed that genomic gains were much more frequent than losses which were observed in only four cases. The chromosomal regions mostly affected are shown in Table 2 . Interestingly, these gained regions contained important genes involved on cell-cell adhesion process (such as R-Cadherin) or tumor development (kallikreins).
With these findings it could be argued that changes can be rather unspecific and because of changes associated with the cell expansion process. To analyze whether non-expanded MSCs could have genomic changes a sorting process was performed. It is well known that MSCs have no specific markers 14, 15 but it has been recently published that a bright expression for CD73 and CD271 markers allows to enrich in MSCs 21 cells obtained by this method (CD45À, CD34À, CD73 and CD 271 bright) also showed genomic changes and once again gains were more frequent than losses. These genomic changes were also confirmed by performing FISH studies using the same probes but in the expanded MSCs from the same patient (Supplementary Figure 6) . These data confirm the presence of genomic changes in MSCs from MDS patients and that the same changes are also present after they were cultured. However, it cannot be excluded that the expansion process could increase the genomic changes observed in expanded population.
An interesting observation of the present study was the finding that MSC from different MDS patients clustered into two clearly separated branches when an unsupervised analysis was performed. In cluster II the MSC from all patients with 5qÀ syndrome were grouped together with the MSC from another patient that, curiously, was not diagnosed as having 5qÀ syndrome because only a low proportion of cells (4%) showed this alteration by FISH but on morphological ground it was similar to 5qÀ syndrome patients (hypoplastic erythropoiesis and hypolobulated megakaryocytes in a patient with anemia and a normal platelet count). These features suggest that BM stroma and/or their MSC precursors are involved in the pathophysiology of MDS. Moreover, our data revealed in the 5qÀ syndrome samples the existence of a singular genomic profile, including the overexpression of some genomic regions (7p22. 3, 19p13.3, 19p13.11) , which could play an important role in the pathogenesis and disease characteristics. It has been recently proposed that the most likely model for MDS could be a dual pathogenesis including hematopoietic stem cells abnormalities and an abnormal BM 'milieu'. In the 5qÀ syndrome the defective erythropoiesis is secondary to a defect in ribosomal protein function but this abnormality does not explain the growth advantage of hematopoietic stem cells suggesting that other abnormalities could be involved in the pathogenesis of this MDS subtype. 35 It must be stressed that the 5qÀ syndrome represents a very well defined MDS subtype and has been recently accepted as a distinct entity by the WHO classification with clearly distinct clinical and prognostic features that differ from those of the other MDS.
The role of the microenvironment in the tumor development was originally proposed by Paget in his 'seed and soil' hypothesis. 36 Recent reports have shown that some genetic changes occur in the stroma during the earliest stages of human carcinogenesis. 37 This genetically unstable stroma may facilitate the growth of malignant clonal cells 38, 39 leading to a 'permissive milieu'. The microenvironment in MDS has been proposed to play a key role in the MDS development and new treatment strategies are being developed for these targets. 2, 40, 41 Our results illustrate that MSC from MDS display not only distinct phenotypic and growth characteristics but also singular genomic changes, some of them specially associated with particular MDS subtypes.
